Placeholder

FACULTY

Rajesh Mohandas

Chief of Medical Academic Area

Medicine - Nephrology

Academic Office:

LSUHSC School of Medicine 
1542 Tulane Avenue, 
New Orleans, LA 70112

504-568-8655

 

Clinical Office:

University Medical Center
2000 Canal Street
New Orleans, LA 70112

504-584-6103

 

Bio

Rajesh Mohandas MD MPH FASN is an Associate Professor of Medicine and Chief of the Section of Nephrology and Hypertension at Louisiana State University Health Sciences Center in New Orleans. He completed a fellowship in nephrology at the University of Florida (UF) on a T32 grant from the NIH. He joined the faculty in 2011 and was promoted to Associate Professor with tenure in 2018. He joined LSUHSC and UMC in March 2022. His clinical focus in on hypertension and chronic kidney disease. His laboratory studies the molecular mechanisms underlying the cardiovascular complications of kidney disease. His research has been published in high impact journals and funded by the National Institute of Health and the Veteran’s Administration.

My Little Something Extra:
In his spare time Dr. Mohandas loves to spend time with his family and experience the rich food and music scene New Orleans has to offer. He loves the outdoors, tennis, and ran his first half-marathon in 2021.

 

Education

Medical:
1994 - M.D.
Medical College Thirucvananthapuram
Kerala, India

Residency:
1999
New York Medical College
Valhalla, New York

Fellowship:
2011
University of Florida College of Medicine
Gainesville, Florida

Affiliated Hospitals & Clinics

  • University Medical Center
  • Touro Infirmary

Publications

 

  1. Kaur H, Pandey N, Chandaluri L, Shaaban N, Kumar D, Pandit R, Martinez A, Anand SK, Das S, Rohilla S, Arias F, Reece E, Gaddam RR, Murnane KS, Vikram A, Mohandas R, Zhang X, Bhuiyan MAN, Lu XH, Orr AW, Rom O, Yurdagul A Jr, Dhanesha N. Neutrophil integrin α9 impairs efferocytosis and worsens long-term recovery after subarachnoid hemorrhage. Arterioscler Thromb Vasc Biol. 2025;45(10):e497–e511.
  2. Canales MT, Yang S, Westanmo A, Mohandas R, et al. As-needed blood pressure medication and adverse outcomes in VA hospitals. JAMA Intern Med. 2025;185(1):52–60.
  3. Desai R, Unigwe I, Riaz M, Smith SM, Shukla AM, Mohandas R, Jeon N, Park H. Comparative safety of long-acting vs short-acting erythropoiesis-stimulating agents among patients undergoing hemodialysis. Clin Pharmacol Ther. 2024;116(1):217–224.
  4. Desai R, Smith SM, Mohandas R, Brown J, Park H. Risk of fractures with concomitant use of calcium channel blockers and selective serotonin reuptake inhibitors. Ann Pharmacother. 2023.
  5. Do T, Van A, Ataei A, Sharma S, Mohandas R*. Microvascular dysfunction in obesity-hypertension. Curr Hypertens Rep. 2023;25(12):447–453.
  6. Millet LM, Ali MJ, Mohandas R. Practice patterns and clinical outcomes of severe coronary artery disease in dialysis patients. Int J Cardiol. 2023;382:1–2.
  7. Sharma RK, Kamble SH, Krishnan S, Gomes J, To B, Li S, Liu IC, Gumz ML, Mohandas R*. Involvement of lysyl oxidase in the pathogenesis of arterial stiffness in chronic kidney disease. Am J Physiol Renal Physiol. 2023;324(4):F364–F373.
  8. Gillespie N, Mohandas R*. New eGFR equations: implications for cardiologists and racial inequities. Am Heart J Plus. 2023;27:100269.
  9. Meariman JK, Zulli H, Perez A, Bajracharya SD, Mohandas R*. Small vessel disease: connections between the kidney and the heart. Am Heart J Plus. 2023;26:100257.
  10. Ejaz AA, Mohandas R, Beaver TM, Johnson RJ. A crystal-independent role for uric acid in acute kidney injury associated with tumor lysis syndrome. J Am Soc Nephrol. 2023;34(1):175.
  11. Desai R, Park H, Brown JD, Mohandas R, Pepine CJ, Smith SM. Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in resistant hypertension. Hypertension. 2022;79(10):2305–2315.
  12. Desai R, Park H, Brown JD, Mohandas R, Smith SM. Norepinephrine reuptake inhibitors and cardiovascular outcomes in hypertension and depression. Pharmacotherapy. 2022;42(6):472–482.
  13. Ozrazgat-Baslanti T, Loftus TJ, Mohandas R, et al. Clinical trajectories of acute kidney injury in surgical sepsis. Ann Surg. 2022;275(6):1184–1193.
  14. Mohandas R, Douma LG, Scindia Y, Gumz ML. Circadian rhythms and renal pathophysiology. J Clin Invest. 2022;132(3):e148277.
  15. Ruchi R, Bozorgmehri S, Chamarthi G, Orozco T, Mohandas R, et al. Kidney disease education services and vascular access outcomes. Kidney360. 2021;3(1):91–98.
  16. Ozrazgat-Baslanti T, Loftus TJ, Ren Y, et al. Persistent acute kidney injury and mortality. BMJ Health Care Inform. 2021;28(1):e100458.
  17. Shukla AM, Bozorgmehri S, Ruchi R, Mohandas R, et al. Utilization of CMS kidney disease education services. Perit Dial Int. 2021;41(5):453–462.
  18. Mohandas R, Chamarthi G, Segal MS. Nonatherosclerotic vascular abnormalities in CKD. Cardiol Clin. 2021;39(3):415–425.
  19. Mohandas R*, Chamarthi G, Bozorgmehri S, et al. PRN antihypertensive medications and adverse outcomes. Hypertension. 2021;78(2):516–524.
  20. Koratala A, Chamarthi G, Touyz RM, et al. Renovascular hypertension: one size does not fit all. Hypertension. 2021;77(4):1022–1028.
  21. Bozorgmehri S, Aboud H, Chamarthi G, et al. Early dialysis initiation and mortality. Hemodial Int. 2021;25(2):188–197.
  22. Krishnan S, Suarez-Martinez AD, Bagher P, et al. Microvascular dysfunction and kidney disease. Microcirculation. 2021;28(3):e12661.
  23. Mohandas R*, Diao Y, Chamarthi G, et al. Circulating endothelial cells and outcomes in hemodialysis. Semin Dial. 2021;25(2):188–197.
  24. Sharma RK, Li J, Krishnan S, et al. ACE2 in cardiorenal diseases. Clin Sci (Lond). 2021;135(1):1–17.
  25. Shukla AM, Segal MS, Pepine CJ, et al. Cardiovascular disease in kidney disease study. Am J Nephrol. 2021;52(1):36–44.
  26. Bandyopadhyay S, Lysak N, Adhikari L, et al. Urinary molecular signature of early sepsis. Crit Care Explor. 2020;2(10):e0195.
  27. Dass B, Dimza M, Singhania G, et al. ROAD-HF study design. Am J Cardiovasc Drugs. 2020;20(4):373–380.
  28. Mohandas R, Segal MS. Roxadustat for anemia in CKD. N Engl J Med. 2020;383.
  29. Mohandas R, Dass B, Ejaz AA. VEGF and endothelin-1 in acute kidney injury. Am J Kidney Dis. 2019;74(5):712–713.
  30. Ruchi R, Bozorgmehri S, Ozrazgat-Baslanti T, et al. Opioid safety in ESRD. Pain Res Manag. 2019;2019:3865924.
  31. Mohandas R, Dass B, Ejaz AA. Contrast-associated acute kidney injury. N Engl J Med. 2019;381(13):1295.
  32. Olaoye OA, Masten SH, Mohandas R, Gumz ML. Circadian clock genes in diabetic kidney disease. Curr Diab Rep. 2019;19(7):42.
  33. Ejaz AA, Johnson RJ, Shimada M, Mohandas R, et al. Role of uric acid in AKI. Nephron. 2019;142(4):275–283.
  34. Pourafshar N, Karimi A, Wen X, et al. Mycophenolic acid levels in lupus nephritis. Nephrol Dial Transplant. 2019;34(1):83–89.
  35. Rodriguez C, Chi YY, Chiu KH, et al. Arterial compliance in pregnancy. Physiol Rep. 2018;6(24):e13947.
  36. Kilar CR, Diao Y, Sautina L, et al. β-common receptor activation and vasodilation. Physiol Rep. 2018;6(12):e13751.
  37. Kilar CR, Sekharan S, Sautina L, et al. β-common receptor inhibitory peptide. Peptides. 2018;104:1–6.
  38. Li WY, Yu G, Hogan RM, Mohandas R, et al. Bioavailability of milk thistle formulations. Clin Ther. 2018;40(1):103–113.
  39. Koratala A, Ejaz AA, Mohandas R. Calciphylaxis of the breast. BMJ Case Rep. 2016;2016:bcr2016216665.
  40. Diao Y, Mohandas R, Lee P, et al. Type I interferon effects on arterial wall. Arterioscler Thromb Vasc Biol. 2016;36(2):266–273.
  41. Segal MS, Srinivas TR, Mohandas R, et al. Allopurinol and blood pressure control. J Am Soc Hypertens. 2015;9(8):610–619.
  42. Agrawal S, Agrawal N, Garg J, Mohandas R, et al. Spironolactone in heart failure and CKD. Am J Med Sci. 2015;350(2):147–151.
  43. Mohandas R, Segal MS, Huo T, et al. Renal function and microvascular dysfunction. PLoS One. 2015;10(5):e0125374.
  44. Ejaz AA, Pourafshar N, Mohandas R, et al. Tumor lysis syndrome prediction models. PLoS One. 2015;10(3):e0119497.
  45. Mohandas R, Segal M, Srinivas TR, et al. Mild renal dysfunction and outcomes in women with chest pain. Am Heart J. 2015;169(3):412–418.
  46. Mohandas R, Anderson RD, Pepine CJ. Acute kidney injury after TAVR. Am J Nephrol. 2015;41(4-5):370–371.
  47. Mohandas R, Sautina L, Beem E, et al. Uric acid inhibition of DPP-IV. Exp Cell Res. 2014;326(1):136–142.
  48. Ejaz AA, Mohandas R. Are diuretics harmful in AKI? Curr Opin Nephrol Hypertens. 2014;23(2):155–160.
  49. Mohandas R, Sautina L, Li S, et al. Angiogenic cells and coronary flow reserve (WISE). PLoS One. 2013;8(12):e81595.
  50. Mohandas R*, Casey MJ, Cook RL, et al. Disparities in donor kidney allocation. Clin J Am Soc Nephrol. 2013;8(12):2158–2164.
  51. Asmar A, Iqbal S, Mohandas R, et al. Renal support in AKI. Minerva Urol Nefrol. 2013;65(1):51–60.
  52. Asmar A, Mohandas R, Wingo CS. Hypokalemia management. Am J Kidney Dis. 2012;60(3):492–497.
  53. Mohandas R, Ejaz AA. Evening antihypertensive dosing. Evid Based Med. 2012;17(4):116–117.
  54. Mohandas R, Segal MS. Endothelial progenitor cells in CKD. Blood Purif. 2010;29(2):158–162.
  55. Mohandas R, Johnson RJ. Uric acid and kidney disease risk. J Am Soc Nephrol. 2008;19(12):2251–2253.
  56. Mohandas R, Gupta KL. Managing thyroid dysfunction in the elderly. Postgrad Med. 2003;113(5):54–58.
  57. Mohandas R, Poduval RD, Unnikrishnan D, Corpuz M. Clostridium ramosum bacteremia and osteomyelitis. Infect Dis Clin Pract. 2001;10(2):123–124.
  58. Poduval RD, Mohandas R, Unnikrishnan D, Corpuz M. Clostridium cadaveris bacteremia in an immunocompetent host. Clin Infect Dis. 1999;29(5):1354–1355.